Results 211 to 220 of about 93,605 (270)

A multicriteria model for prioritizing 5G network deployment with Monte Carlo stability analysis: A case study in Magdalena, Colombia. [PDF]

PLoS One
Martínez Abuabara R, Robles CA, Camargo LL.   +2 more
europepmc   +1 more source

A Combined Model‐Based Meta‐Analysis of Aggregated and Individual FEV1 Data From Randomized COPD Trials

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Model‐based meta‐analysis allows integration of aggregated‐level data (AD) from different clinical trials in one model to assess population efficacy/safety. However, AD is limited in individual‐level information, while individual‐patient‐level data (IPD) are hard to obtain. Combined modeling may take advantage of both sources.
Liang Yang, Carolina Llanos‐Paez, Shuying Yang, Claire Ambery, Alienor Berges, Maria C. Kjellsson, Mats O. Karlsson   +6 more
wiley   +1 more source

Analyzing lognormal data: A nonmathematical practical guide. [PDF]

Pharmacol Rev
Motulsky HJ, Head T, Clarke PBS.
europepmc   +1 more source

Tackling High Dimensionality in QSP: Guiding Model Order Reduction With Index Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Quantitative systems pharmacology (QSP) models offer a useful platform to integrate drug pharmacology with knowledge about biological mechanisms across multiple scales and data sources into a unified quantitative framework. This makes them invaluable to address many relevant questions in drug research and development.
Johannes Tillil, Wilhelm Huisinga, Jane Knöchel   +2 more
wiley   +1 more source

Cost-effectiveness of combining finerenone and sodium-glucose cotransporter 2 inhibitors with standard of care for patients with chronic kidney disease and type 2 diabetes in China. [PDF]

Ren Fail
Hu Z, Jin W, Lou S, Zhang L.
europepmc   +1 more source

Immunogenicity Publication Bias and Its Consequences for Predictive Models: A Call for Transparent Reporting

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Understanding immunogenicity is crucial to improving therapeutic protein development. By comparing Phase I to III antidrug antibody (ADA) incidence data of Roche‐internal and approved monoclonal antibodies, we demonstrate a bias toward lower ADA incidence in published data, partly because ADA data from early trials—often discontinued for ...
Sophie Tascedda, Zicheng Hu, Hans Peter Grimm, Linnea C. Franssen   +3 more
wiley   +1 more source

Exploring the epidemiological characteristics of Mpox in the Arab Gulf countries. [PDF]

Sci Rep
Althobaity YM, Tildesley MJ.
europepmc   +1 more source

Latent Variable Indirect Response Modeling of Cendakimab Exposure–Response for Longitudinal Dysphagia Days Using a Combined Uniform‐Binomial Likelihood Framework

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT To characterize the relationship between cendakimab exposure and the longitudinal efficacy endpoint dysphagia days (DD), E–R analyses were performed using data from the EE‐001 study (N = 427) with eosinophilic esophagitis. DD—a bounded, discrete endpoint assessed over 14‐day period via modified daily symptom diary (mDSD)—was modeled using a ...
Shengnan Du, Jessica Wojciechowski, Peijin Zhang, Urvi Aras, Bindu Murthy, Jun Shen, Anna Kondic, Chuanpu Hu   +7 more
wiley   +1 more source

Isolating selective from non-selective forces using site frequency ratios. [PDF]

PLoS Genet
Hey J, Pavinato VAC.
europepmc   +1 more source

Rapid Serological Detection of Anti‐GM‐CSF Autoantibodies in Autoimmune Pulmonary Alveolar Proteinosis Using a Novel Immunochromatographic Test

Respirology, Volume 31, Issue 2, Page 184-192, February 2026.
We developed a novel ICT with high clinical performance that can distinguish APAP patients from those with other pulmonary diseases. The rapid and simple detection of GMAbs in serum provided a new practical method for the diagnosis of APAP. See related editorial ABSTRACT Background and Objectives Anti‐GM‐CSF autoantibodies (GMAbs) are essential ...
Chika Narita, Kenjiro Shima, Jun‐ichiro Sekiguchi, Yasuyuki Ozeki, Makoto Akiwa, Shohei Koike, Sachiko Yuki, Keiichi Akasaka, Toshiaki Kikuchi, Nobutaka Kitamura, Koh Nakata   +10 more
wiley   +1 more source